Table 2.
Baseline characteristics of the study participants.
| Placebo (n = 20) |
Herb formula (n = 20) |
|
|---|---|---|
| Age, years | 54.7 ± 9.1 | 57.5 ± 8.4 |
| Males, n (%) | 10 (50) | 6 (30) |
| Body weight, kg | 71.3 ± 17.2 | 65.0 ± 10.7 |
| Body mass index, kg/m2 | 27.2 ± 4.7 | 25.9 ± 2.8 |
| Body fat, % | 31.5 ± 7.3 | 31.9 ± 6.1 |
| Waist, cm | 94.3 ± 12.7 | 87.7 ± 7.7 |
| SBP, mmHg | 119.5 ± 12.4 | 118.9 ± 10.8 |
| DBP, mmHg | 77.1 ± 9.6 | 73.6 ± 9.6 |
| Pulse, bpm | 71.1 ± 10.1 | 67.4 ± 7.5 |
| Diabetes, n (%) | 8 (40) | 11 (55) |
| Hypertension, n (%) | 14 (70) | 10 (50) |
| FH, n (%) | 7 (35) | 5 (25) |
| On lipid-lowering treatment | 9 (45) | 8 (40) |
| On antidiabetic treatment | 5 (25) | 5 (25) |
| Baseline TC, mmol/L | 5.39 ± 0.89 | 5.90 ± 1.17 |
| Baseline HDL-C, mmol/L | 1.29 ± 0.39 | 1.28 ± 0.25 |
| Baseline TG, mmol/L | 2.35 ± 1.18 | 2.00 ± 0.71 |
| Baseline LDL-C, mmol/L | 3.04 ± 0.82 | 3.72 ± 1.17* |
| Baseline non-HDL-C, mmol/L | 4.10 ± 0.68 | 4.63 ± 1.13 |
| Fasting glucose, mmol/L | 5.57 ± 1.23 | 5.84 ± 2.17 |
| HbA1c, % | 6.57 ± 0.98 | 6.59 ± 0.83 |
DBP: diastolic blood pressure; TC: total cholesterol; FH: familial hypercholesterolaemia; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; TG: triglycerides.
*P < 0.05 versus placebo.